{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:39:47Z","timestamp":1792823987293,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001287","name":"Elsa U. Pardee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R 01CA280097"],"award-info":[{"award-number":["R 01CA280097"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA297220"],"award-info":[{"award-number":["R01CA297220"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA248033"],"award-info":[{"award-number":["R01CA248033"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218862","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:46:54Z","timestamp":1790725614000},"page":"218862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PYGO2 ablation promotes lymphoid organization and STING-dependent antitumor immunity in prostate cancer"],"prefix":"10.1016","volume":"661","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9592-2053","authenticated-orcid":false,"given":"Yini","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7630-3089","authenticated-orcid":false,"given":"Nipuni","family":"Barupala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-5293","authenticated-orcid":false,"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0284-6478","authenticated-orcid":false,"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218862_bib1","article-title":"Cancer statistics","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218862_bib2","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2010.34.5025","article-title":"Immunotherapy for prostate cancer: biology and therapeutic approaches","volume":"29","author":"Cha","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218862_bib3","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-17-0019","article-title":"Immunotherapy of prostate cancer: facts and hopes","volume":"23","author":"Bilusic","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218862_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/aja202283","article-title":"Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer","volume":"25","author":"Zhu","year":"2023","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.canlet.2026.218862_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218862_bib6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","article-title":"Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses","volume":"14","author":"Hirz","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218862_bib7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218862_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218862_bib9","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218862_bib10","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218862_bib11","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"Immunogenomic landscape of neuroendocrine prostate cancer","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218862_bib12","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","article-title":"The genomic and epigenomic landscape of double-negative metastatic prostate cancer","volume":"83","author":"Lundberg","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218862_bib13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41391-022-00524-7","article-title":"A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer","volume":"25","author":"Brown","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.canlet.2026.218862_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","article-title":"The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression","volume":"36","author":"Su","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218862_bib15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.annonc.2025.05.008","article-title":"Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study","volume":"36","author":"Gratzke","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218862_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218862_bib17","doi-asserted-by":"crossref","first-page":"S995","DOI":"10.1016\/j.annonc.2024.08.1733","article-title":"1652P SAABR: single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)","volume":"35","author":"Rathkopf","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218862_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218862_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218862_bib20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218862_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/pros.24684","article-title":"Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer","volume":"84","author":"Shahait","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218862_bib22","first-page":"501","volume":"5","author":"Wang","year":"2025"},{"key":"10.1016\/j.canlet.2026.218862_bib23","article-title":"Characteristics of tertiary lymphoid structures in prostate cancer and the impact of neoadjuvant therapy on their formation and maturation","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218862_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.20181216","article-title":"Type I interferon induces CXCL13 to support ectopic germinal center formation","volume":"216","author":"Denton","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218862_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001906","article-title":"STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment","volume":"9","author":"Chelvanambi","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218862_bib26","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/s41590-025-02259-8","article-title":"Simultaneous STING and lymphotoxin-\u03b2 receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity","volume":"26","author":"Sawada","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218862_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009368","article-title":"Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy","volume":"12","author":"Al-Janabi","year":"2024","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218862_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1196829","article-title":"Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models","volume":"14","author":"Papaevangelou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218862_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.molcel.2008.03.011","article-title":"Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex","volume":"30","author":"Fiedler","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218862_bib30","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1128\/MCB.00465-10","article-title":"Pygo2 associates with MLL2 histone methyltransferase and GCN5 histone acetyltransferase complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion","volume":"30","author":"Chen","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218862_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.stem.2013.04.012","article-title":"Chromatin effector Pygo2 mediates Wnt-notch crosstalk to suppress luminal\/alveolar potential of mammary stem and basal cells","volume":"13","author":"Gu","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2026.218862_bib32","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-17-3564","article-title":"An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer","volume":"78","author":"Lu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218862_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/jclinpath-2017-204718","article-title":"PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy","volume":"71","author":"Kao","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.canlet.2026.218862_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade4656","article-title":"Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer","volume":"8","author":"Zhu","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218862_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218862_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218862_bib37","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1038\/s41467-021-25624-1","article-title":"Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse","volume":"12","author":"Taavitsainen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218862_bib38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary lymphoid structures in anticancer immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218862_bib39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218862_bib40","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218862_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","article-title":"Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling","volume":"179","author":"Coppola","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218862_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noy148.565","article-title":"IMMU-62. LOW-GRADE glioma exclude CD8 T cells, WHICH IS accompanied by low expression of chemo-attractants, not immunogenic antigens","volume":"20","author":"Weenink","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218862_bib43","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218862_bib44","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.semcancer.2022.06.005","article-title":"Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges","volume":"86","author":"Indini","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218862_bib45","article-title":"An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure","volume":"5","author":"Liu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218862_bib46","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1158\/0008-5472.CAN-16-0902","article-title":"Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome","volume":"76","author":"You","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218862_bib47","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218862_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218862_bib49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ebiom.2015.07.017","article-title":"Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study","volume":"2","author":"Ross-Adams","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2026.218862_bib50","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.cell.2022.02.012","article-title":"Tumor-reactive antibodies evolve from non-binding and autoreactive precursors","volume":"185","author":"Mazor","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218862_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109422","article-title":"Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts","volume":"36","author":"Rodriguez","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218862_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25112496","article-title":"Resolving DNA damage: epigenetic regulation of DNA repair","volume":"25","author":"Karakaidos","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2026.218862_bib53","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/2159-8290.CD-22-1220","article-title":"The DNA damage response and inflammation in cancer","volume":"13","author":"Klapp","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218862_bib54","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41590-026-02505-7","article-title":"Differential assembly of mouse and human tumor microenvironments","volume":"27","author":"Courau","year":"2026","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218862_bib55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218862_bib56","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: an intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218862_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690105","article-title":"STINGing the tumor microenvironment to promote therapeutic tertiary lymphoid structure development","volume":"12","author":"Filderman","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218862_bib58","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature09677","article-title":"SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression","volume":"470","author":"Ding","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218862_bib59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218862_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218862_bib61","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-15-1456","article-title":"STING promotes the growth of tumors characterized by low antigenicity via IDO activation","volume":"76","author":"Lemos","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218862_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/JCI192397","article-title":"Targeting STING-induced immune evasion with nanoparticulate binary pharmacology improves tumor control in mice","volume":"135","author":"Meng","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218862_bib63","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1158\/2326-6066.CIR-20-0692","article-title":"Oncogenic KIT modulates type I IFN-mediated antitumor immunity in GIST","volume":"9","author":"Liu","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218862_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001182","article-title":"Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity","volume":"8","author":"Lemos","year":"2020","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218862_bib65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:25:16Z","timestamp":1792823116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":65,"alternative-id":["S0304383526006269"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218862","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PYGO2 ablation promotes lymphoid organization and STING-dependent antitumor immunity in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218862"}}